¼¼°èÀÇ ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷ Ä¡·á ½ÃÀå
Autoimmune Hemolytic Anemia Treatment
»óǰÄÚµå : 1773982
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 465 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷ Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 10¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 7¾ï 7,120¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷ Ä¡·á ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 5.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 10¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ "¿Â¿­ ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷ Ä¡·á"´Â CAGR 6.3%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 5¾ï 1,510¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Äݵå ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷ Ä¡·á ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 1,010¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷ Ä¡·á ½ÃÀåÀº 2024³â¿¡ 2¾ï 1,010¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2024³âºÎÅÍ 2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 8.5%¸¦ ´õµë¾î, 2030³â±îÁö 2¾ï 1,110¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.5%¿Í 5.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷ Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷ÀÇ Ä¡·á »óȲÀº ¾î¶»°Ô ¹ßÀüÇϰí Àִ°¡?

ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷(AIHA)Àº ¸é¿ª°è°¡ ÀûÇ÷±¸¸¦ ÆÄ±«ÇÏ´Â ÁúȯÀÌÁö¸¸, Ä¡·á ¿É¼ÇÀº Å©°Ô ¹ßÀüÇß½À´Ï´Ù. ÇöÀç Ä¡·á¹ýÀ¸·Î´Â ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å, ¸é¿ª¾ïÁ¦Á¦, ÁßÁõ ȯÀÚÀÇ °æ¿ì ºñÀåÀýÁ¦¼ú µîÀÌ ÀÖ½À´Ï´Ù. ´ÜŬ·ÐÇ×ü ¹× Ç¥Àû »ý¹°ÇÐÀû Á¦Á¦¿Í °°Àº »õ·Î¿î Ä¡·á¹ýÀº ºÎÀÛ¿ëÀ» ÁÙÀ̸鼭 ÀÌ Áúº´À» °ü¸®ÇÒ ¼ö ÀÖ´Â »õ·Î¿î ¹æ¹ýÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áø´Ü µµ±¸ÀÇ ¹ßÀüÀ¸·Î Á¶±â ¹ß°ßÀÌ °¡´ÉÇØÁ® Àû½Ã¿¡ È¿°úÀûÀ¸·Î °³ÀÔÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº AIHA ȯÀÚµéÀ» À§ÇÑ ¸ÂÃãÀÇ·á¿Í Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÇ Áõ°¡¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù.

AIHA Ä¡·áÀÇ Çõ½ÅÀ» ÁÖµµÇÏ´Â Æ®·»µå´Â ¹«¾ùÀϱî?

¸î °¡Áö Æ®·»µå°¡ AIHA Ä¡·á ½ÃÀåÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦¿Í ´ÜŬ·ÐÇ×üÀÇ µîÀåÀº Ä¡·á ±âÁØÀ» ÀçÁ¤ÀÇÇϰí AIHA¸¦ °ü¸®ÇÒ ¼ö Àִ ǥÀûÈ­µÈ ¼Ö·ç¼ÇÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ±Ùº»ÀûÀÎ À¯ÀüÀû, ¸é¿ªÇÐÀû ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ¿¬±¸´Â »õ·Î¿î Ä¡·á¹ýÀÇ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ȯÀÚ Áß½ÉÀÇ Ä¡·á°¡ °­Á¶µÇ¸é¼­ ´ú ħ½ÀÀûÀÎ Ä¡·á¹ý °³¹ß ¹× ¾à¹°ÀÇ Á¦Çü °³¼±¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º´¿ë¿ä¹ýÀ» ¸ð»öÇÏ´Â ÀÓ»ó½ÃÇèÀÌ Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ´Â °¡´É¼ºÀ» º¸¿©ÁÜÀ¸·Î½á ±â¼ú Çõ½ÅÀÇ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.

AIHA Ä¡·áÀÇ ¹ßÀüÀ¸·Î ȯÀÚµéÀº ¾î¶² ÇýÅÃÀ» ¹Þ°í Àִ°¡?

AIHA ȯÀÚµéÀº ´õ ³ªÀº Áúº´ Á¶Àý, ´õ ÀûÀº ºÎÀÛ¿ë, ´õ ³ªÀº »îÀÇ ÁúÀ» Á¦°øÇÏ´Â Ä¡·áÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ¸®Åö½Ã¸¿°ú °°Àº »ý¹°ÇÐÀû Á¦Á¦´Â Ç¥Àû ¸é¿ª Á¶ÀýÀ» ÅëÇØ Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ¼öÇ÷°ú öºÐ ų·¹ÀÌÆ® ¿ä¹ýÀ» Æ÷ÇÔÇÑ ÁöÁö¿ä¹ýÀÇ ¹ßÀüÀº ÀÌ Áúȯ°ú °ü·ÃµÈ ÇÕº´Áõ¿¡ ´ëóÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÎ½Ä °³¼±°ú Á¶±â Áø´ÜÀ» À§ÇÑ ³ë·ÂÀ¸·Î ȯÀÚµéÀÌ Àû½Ã¿¡ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾î Áúº´ÀÇ ½É°¢¼º°ú Àå±âÀûÀÎ °Ç°­ ¿µÇâÀ» ÁÙÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº AIHA Ä¡·áÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½ÃŰ´Â µ¥ ÀÖ¾î ÁøÀüÀÌ ÀÌ·ç¾îÁö°í ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù.

ÀÚ°¡¸é¿ª¼º ¿ëÇ÷¼º ºóÇ÷ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀϱî?

AIHA Ä¡·á ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº Áúº´ À¯º´·ü Áõ°¡, »ý¹°ÇÐÀû Á¦Á¦ ¹× Ç¥Àû Ä¡·áÁ¦ÀÇ ¹ßÀü, ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ ÀνÄÀÇ Áõ°¡ÀÔ´Ï´Ù. Çõ½ÅÀû Ä¡·á¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀº Çõ½Å ½Å¾àÀÇ Á¶±â ½ÂÀÎ µî ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µ¿¹ÝÁø´Ü ¾à¹°ÀÇ °³¹ßÀº ȯÀڵ鿡°Ô ´õ ³ªÀº °á°ú¸¦ º¸ÀåÇϱâ À§ÇØ °³ÀÎÈ­µÈ Ä¡·á Á¢±Ù¹ýÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾àȸ»ç¿Í ¿¬±¸±â°üÀÇ Çù¾÷Àº ÀÌ ºÐ¾ßÀÇ Çõ½ÅÀ» °¡¼ÓÈ­Çϰí ÀÖÀ¸¸ç, Áö¼ÓÀûÀÎ ½ÃÀå È®´ëÀÇ °¡´É¼ºÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(¿Â¿­, ÇÑ·©, ±âŸ À¯Çü), ¾à¹° Á¾·ù(ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å, ¸é¿ª¾ïÁ¦Á¦, ±âŸ ¾à¹° Á¾·ù), Åõ¿© °æ·Î(ÁÖ»çÁ¦, °æ±¸Á¦, ±âŸ Åõ¿© °æ·Î), À¯Åë ä³Î(º´¿ø ¾à±¹ À¯Åë ä³Î, ¼Ò¸Å ¾à±¹ À¯Åë ä³Î, ¿Â¶óÀÎ ¾à±¹ À¯Åë ä³Î)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Autoimmune Hemolytic Anemia Treatment Market to Reach US$1.0 Billion by 2030

The global market for Autoimmune Hemolytic Anemia Treatment estimated at US$771.2 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Warm Autoimmune Hemolytic Anemia Treatment, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$515.1 Million by the end of the analysis period. Growth in the Cold Autoimmune Hemolytic Anemia Treatment segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$210.1 Million While China is Forecast to Grow at 8.5% CAGR

The Autoimmune Hemolytic Anemia Treatment market in the U.S. is estimated at US$210.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$211.1 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Autoimmune Hemolytic Anemia Treatment Market - Key Trends & Drivers Summarized

How Is the Treatment Landscape Evolving for Autoimmune Hemolytic Anemia?

Autoimmune hemolytic anemia (AIHA), a condition in which the immune system destroys red blood cells, has seen significant advancements in treatment options. Current approaches include corticosteroids, immunosuppressive drugs, and splenectomy for severe cases. Emerging therapies, such as monoclonal antibodies and targeted biologics, are providing new avenues for managing the disease with fewer side effects. Additionally, advancements in diagnostic tools are enabling earlier detection, ensuring timely and effective intervention. These developments reflect the growing focus on personalized and precision medicine for AIHA patients.

What Trends Are Driving Innovation in AIHA Treatment?

Several trends are shaping the AIHA treatment market. The rise of biologics and monoclonal antibodies is redefining treatment standards, offering targeted solutions for managing the condition. Research into underlying genetic and immune mechanisms is paving the way for novel therapies. The growing emphasis on patient-centric care has spurred the development of less invasive treatment options and improved drug formulations. Additionally, clinical trials exploring combination therapies are showing promise in enhancing treatment efficacy, creating opportunities for innovation.

How Are Patients Benefiting from Advances in AIHA Treatment?

Patients with AIHA are benefiting from treatments that offer better disease control, fewer side effects, and improved quality of life. Biologic therapies, such as rituximab, have revolutionized care by providing targeted immune modulation. Advances in supportive care, including blood transfusions and iron chelation, are addressing complications associated with the condition. Furthermore, increased awareness and early diagnostic initiatives are helping patients access timely treatment, reducing disease severity and long-term health impacts. These advancements highlight the progress in addressing unmet needs in AIHA care.

What Drives the Growth in the Autoimmune Hemolytic Anemia Treatment Market?

The growth in the AIHA treatment market is driven by rising disease prevalence, advancements in biologics and targeted therapies, and increased awareness of autoimmune disorders. Regulatory support for innovative treatments, including fast-track approvals for breakthrough drugs, is fostering market growth. The development of companion diagnostics is also enabling personalized treatment approaches, ensuring better outcomes for patients. Additionally, collaborations between pharmaceutical companies and research institutions are accelerating innovation in this space, underscoring the potential for sustained market expansion.

SCOPE OF STUDY:

The report analyzes the Autoimmune Hemolytic Anemia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Warm Autoimmune Hemolytic Anemia Treatment, Cold Autoimmune Hemolytic Anemia Treatment, Other Types); Drug Class (Corticosteroids, Immunosuppressive Agents, Other Drug Classes); Administration Route (Injectable Administration, Oral Administration, Other Administration Routes); Distribution Channel (Hospital Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel, Online Pharmacy Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â